AlphaFold predicted structure
PCYT2 · Q99447

Mean pLDDT
86.1/ 100
Confident
389 residues
Confidence breakdown
- Very high(≥ 90)67%
- Confident(70–90)17%
- Low(50–70)3%
- Very low(< 50)13%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
phosphate cytidylyltransferase 2, ethanolamine
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
Adult onset hereditary spastic paraplegia
BIALLELIC, autosomal or pseudoautosomalChildhood onset hereditary spastic paraplegia
BIALLELIC, autosomal or pseudoautosomalDDG2P
BIALLELIC, autosomal or pseudoautosomalEarly onset or syndromic epilepsy
BIALLELIC, autosomal or pseudoautosomalHereditary spastic paraplegia
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalHereditary neuropathy or pain disorder
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalspastic paraplegia 82, autosomal recessive
complex hereditary spastic paraplegia
neurodegenerative disease
Global developmental delay
Intellectual disability
Spastic paraparesis
Seizure
Developmental regression
Cerebral atrophy
Cerebellar atrophy
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Ethanolamine-phosphate cytidylyltransferase
Ethanolamine-phosphate cytidylyltransferase that catalyzes the second step in the synthesis of phosphatidylethanolamine (PE) from ethanolamine via the CDP-ethanolamine pathway (PubMed:31637422, PubMed:9083101). Phosphatidylethanolamine is a dominant inner-leaflet phospholipid in cell membranes, where it plays a role in membrane function by structurally stabilizing membrane-anchored proteins, and participates in important cellular processes such as cell division, cell fusion, blood coagulation, and apoptosis (PubMed:9083101)
PCYT2 · Q99447

Mean pLDDT
86.1/ 100
Confident
389 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0